



<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/540,803
				Filing Date	June 23, 2005
				First Named Inventor	Green, Daniel T.
				Art Unit	1654
				Examiner Name	Maury A. Audet
Sheet	1	of	4	Attorney Docket Number	022354-000310US

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1	3,897,551	07-28-1975	Bromer	
	2	4,492,684	01-08-1985	Goosen et al.	
	3	4,498,843	02-12-1985	Schneider et al.	
	4	4,826,763	05-02-1989	Norris et al.	
	5	4,839,174	06-13-1998	Baker et al.	
	6	4,943,435	07-24-1990	Baker et al.	
	7	5,234,903	08-10-1993	Nho et al.	
	8	5,359,030	10-25-1994	Ekwuribe	
	9	5,445,832	08-29-1995	Orsolini et al.	
	10	5,637,568	08-10-1997	Orsolini et al.	
	11	5,843,604	07-01-1997	Angeles Uribe et al.	
	12	5,843,607	07-01-1997	Okada et al.	
	13	5,707,641	01-13-1998	Gertner et al.	
	14	5,849,322	12-15-1998	Ebert et al.	
	15	5,869,602	02-09-1999	Jonassen et al.	
	16	6,103,233	08-15-2000	Pouletty et al.	
	17	6,107,489	08-22-2000	Krantz et al.	
	18	6,114,304	09-05-2000	Kolterman et al.	
	19	6,191,105	02-20-2001	Ekwuribe et al.	
	20	6,197,333	03-06-2001	Onyuksel et al.	
	21	6,217,893	04-17-2001	Pellet et al.	
	22	6,239,107	05-29-2001	Gozes et al.	
	23	6,277,863	08-21-2001	Krantz et al.	
	24	6,284,727	09-04-2001	Kim et al.	
	25	6,319,510	11-20-2001	Yates	
	26	6,329,336	12-11-2001	Bridon et al.	
	27	6,348,214	02-19-2002	Onyuksel et al.	
	28	6,500,918	12-31-2002	Ezrin et al.	
	29	6,559,122	05-08-2003	Oeswein et al.	
	30	6,573,238	06-03-2003	Shirley et al.	
	31	6,589,548	07-08-2003	Oh et al.	
	32	6,593,295	07-15-2003	Bridon et al.	
	33	6,703,365	03-04-2004	Galloway et al.	

Examiner Signature		Date Considered	10/07
--------------------	--	-----------------	-------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.



PTO/SB/08A&amp;B (07-06)

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)			<b>Complete if Known</b>		
			Application Number	10/540,803	
			Filing Date	June 23, 2005	
			First Named Inventor	Green, Daniel T.	
			Art Unit	1654	
			Examiner Name	Maury A. Audet	
Sheet	2	of	4	Attorney Docket Number	022354-000310US


U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
[Signature]	34	2001/0016643	08-23-2001	Jonassen et al.	
	35	2001/0033858	10-25-2001	Zhang	
	36	2002/0114829	08-22-2002	Onyuksel et al.	
	37	2002/01155920	08-22-2002	New et al.	
	38	2003/0108568	01-12-2003	Bridon et al.	
	39	2004/0110817A1	08-2004	Bernard Hulin	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document <sup>431</sup>			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>o</sup>
		Country Code <sup>2</sup>	Number <sup>4</sup>	Kind Code <sup>45</sup> (if known) <sup>45</sup>				
H	40	EP	0 300 552		01-25-1989	Cordis Europa N.V.		
	41	EP	0442724		08-21-1991	Kirin Amgen Inc.		
	42	EP	0684044		11-29-1995	Johan F. Jensen, et al.		
	43	EP	0816381		01-07-1998	Toshikazu Nakamura, et al.		
	44	EP	1264837		12-11-2002	Nobex Corp.		
	45	WO	8809341		12-01-1988	Robert B. Merrifield		
	46	WO	9703688		02-06-1997	Miriam Kidron et al.		
	47	WO	9724440		07-10-1997	Genentech Inc.		
	48	WO	9808871		03-05-1998	Novo Nordisk A/S		
	49	WO	9831383		07-23-1998	Phoenix Pharmacologics Inc.		
	50	WO	9943708		09-02-1999	Novo Nordisk A/S		
	51	WO	0182874		11-08-2001	Aeropharm Technology Inc.		
	52	WO	0182981		11-08-2001	Aeropharm Technology Inc.		
	53	WO	0222154		03-21-2002	Praecis Pharmaceuticals Inc.		
	54	WO	0232957		04-25-2002	Chugai Seiyaku Kabushiki Kaisha		
	55	WO	0246227		08-13-2002	Eli Lilly and Company		
56	WO	04060387	A1	07-22-2004	Diobex Inc.			

Examiner Signature		Date Considered	10/07
--------------------	--	-----------------	-------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.




<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/540,803
				Filing Date	June 23, 2005
				First Named Inventor	Green, Daniel T.
				Art Unit	1654
				Examiner Name	Maury A. Audet
Sheet	3	of	4	Attorney Docket Number	022354-000310US

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>	
	57	AMERICAN DIABETES ASSOCIATION, "Defining and Reporting Hypoglycemia in Diabetes," Diabetes Care, 28:1245-1249 (2005)	<input type="checkbox"/>	
	58	BEAVEN et al., European J. Biochem., 11:37-42 (1969)	<input type="checkbox"/>	
	59	CHIOU et al., "Adjustment of Blood Sugar Levels with Insulin and Glucagons Eyedrops in Normal and Diabetic Rabbits," J Ocul Pharmacol., 6(3):233-41, Fall 1990	<input type="checkbox"/>	
	60	CHIOU et al., "Treatment of Hypoglycemia with Glucagon Eye Drops," J Ocul Pharmacol., 4(2):179-86, Summer 1988	<input type="checkbox"/>	
	61	CHUANG et al., "Increase of Blood Glucose Concentrations in Diabetic Patients with Glucagon Eyedrops," Zhongguo Yao Li Xue Bao, 13(3):193-7, May 1992	<input type="checkbox"/>	
	62	FABRIS et al., Nasal Administration of Glucagon in the Treatment of Neonatal Hypoglycemia," Minevraa Pediatr. 36(0):525-8, May 31, 1984	<input type="checkbox"/>	
	63	GAMBA et al., Minevra Med. 1977 Nov 3; 68(53):3613-26	<input type="checkbox"/>	
	64	HOULBERT et al., "Continuous Subcutaneous Infusion of Glucagon by Portable Pump in Non Beta Cell Tumor Hypoglycemia," Diabete & Metab. 11(2):125-7, April 1985	<input type="checkbox"/>	
	65	JOSEPH et al., "Oral Delivery of Glucagon-like Peptide-1 in a Modified Polymer Preparation Normalizes Basal Glycaemia in Diabetic db/db Mice," Diabetologia, 43(10):1319-28, Oct 2000	<input type="checkbox"/>	
	66	KAINDL et al., Inn Med. 1972 Dec 15; 27(24):1097-8	<input type="checkbox"/>	
	67	KAINDL et al., Verh Dtsch Ges Inn Med. 1972 Apr; 78:1099-101		
	68	LUND et al., Proc. Natl. Acad. Sci. USA 79:345-349 (1982)		
Examiner Signature			Date Considered	10/07

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.



<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)			<b>Complete if Known</b>		
			Application Number	10/540,803	
			Filing Date	June 23, 2005	
			First Named Inventor	Green, Daniel T.	
			Art Unit	1654	
			Examiner Name	Maury A. Audet	
Sheet	4	of	4	Attorney Docket Number	022354-000310US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	69	MIRALLES et al, "Experience With Intravenous Glucagon Infusions as a Treatment for Resistant Neonatal Hypoglycemia," Arch. Pediatr Adolesc Med., 156(1):999-1004, Oct 2002	
	70	MUHLHAUSER et al., "Experience with Intravenous Glucaagon Infusions as a Treatment for Resistant Neonatal Intramuscula, Subcutaneous, and Intravenous Administration," Diabetes Care, 8(1):39-41 Jan-Feb 1985	
	71	PAOLISSO et al., "Pulsatile Rather Than Continuous Glucagon Infusion Leads To Greater Metabolic Derangements In Insulin-Dependent Diabetic Subjects," Diabete Metabl., 1990, Jan-Feb; 16(1):42-7 (abstract)	
	72	PATZELT et al., "Identification and Processing of Proglucagon in Pancreatic Islets." Nature, 282:260-266 (1979)	
	73	PILLION et al., "Glucagon Administration to the Rat via Eye Drops," J Ocul Pharmacol., 8(4):349-58, Winter 1992	
	74	PILLION et al., "Systemic Absorption of Insulin and Glucagon Applied Topically to the Eyes of Rats and Diabetic Dog," J Ocul Pharmacol Ther., 11(3):238-95, Fall 1995	
	75	PONTIROLI et al., "Metabolic Effects of Intranasally Administered Glucagon: Comparison with Intramuscular and Intravenous Injection," Acta Diabetol Lat.22(2):103-10, April-June 1985	
	76	ROSENFALCK et al., "Nasal Glucagon in the Treatment of Hypoglycaemia in type 1 (Insulin-Dependent) Diabetic Patients," Diabetes Res Clin Pract. 17(1):43-50 July 1992	
	77	STENNINGER et al., "Intranasal Glucagon Treatment Relieves Hypoglycaemia in Children with Type 1 (Insulin-Dependent) Diabetes Mellitus," Diabetologia. 36(10):931-5, Oct 1993	
	78	STURM et al., Structure-Function Studies on Positions 17, 18, and 21 Replacement Analogues of Glucagon: The Importance of Charged Residues and Salt Bridges on Glucagon Biological Activity," J. Med. Chem. 41:2693-2700 (1998)	
	79	WEBB et al., "Glucagon Replacement via Micro-Osmotic Pump Corrects Hypoglycemia and alpha-cell Hyperplasia in Prohome Convertase 2 Knockout Mice," Diabetes 51(2):398-405, Feb 2002	

Examiner Signature		Date Considered	10/07
-----------------------	--	--------------------	-------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.